In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India

Abstract

The study revealed the differential ability of cefepime/taniborbactam and cefepime/zidebactam in tackling carbapenemase-producing Indian clinical isolates that also harbored additional mechanisms of resistance. NDM-expressing E. coli with 4-amino-acid insert in PBP3 are predominately resistant to cefepime/taniborbactam, while the β-lactam enhancer mechanism-based cefepime/zidebactam showed consistent activity against single- or dual-carbapenemase-producing isolates including E. coli with PBP3 inserts.

Determination of potential combination of non‐β‐lactam, β‐lactam, and β‐lactamase inhibitors/β‐lactam enhancer against class D oxacillinases producing Acinetobacter baumannii: Evidence from in‐vitro, molecular docking and dynamics simulation

“…The results obtained were by the binding scores. The study carried out on non‐BL, BL, and BLI/BL enhancer have led us to strongly believe that they have a strong affinity toward OXA‐23, OXA‐24, and OXA‐58, and are bound tightly to them 38 …”

“…The study carried out on non-BL, BL, and BLI/BL enhancer have led us to strongly believe that they have a strong affinity toward OXA-23, OXA-24, and OXA-58, and are bound tightly to them. 38 Based on the results we have acquired through MDS, the binding efficiency of the non-BL/BL has a synergistic impact on OXAs (OXA-23, 24, and 58), but if combined with BLI/BLE, a boost in the activity of BL can be acquired. In this regard, we suggest some combinations of non-BL, BL, and BLI/BL enhancers, which might be effective toward the nosocomial pathogen A. baumannii.…”